Evenity (Romosozumab) Geriatric (65+) Monitoring: Labs, Timelines, and Safety Checks

Why Geriatric Patients Need a Distinct Monitoring Protocol

Patients aged 65 and older account for the vast majority of romosozumab prescriptions, yet age-related organ decline and polypharmacy create monitoring demands that younger adults rarely face. Standard prescribing information does not stratify by age, so clinicians must layer geriatric-specific checkpoints onto the baseline protocol.

In the ARCH trial (N=4,093), the median participant age was 74 years, and 30% of enrolled women were older than 80 [1]. That population profile means the trial's safety signals, particularly the cardiovascular imbalance, already reflect a geriatric cohort. The Endocrine Society's 2020 clinical practice guideline recommends romosozumab only in postmenopausal women at very high fracture risk, defined as a recent osteoporotic fracture within 24 months or a T-score of <-3.0 [2]. Older adults who meet these thresholds are precisely the patients most vulnerable to cardiovascular events, renal impairment, and polypharmacy interactions.

A structured monitoring plan addresses three goals: detecting cardiovascular and metabolic harm early, confirming that bone formation is actually responding, and ensuring the transition to antiresorptive therapy happens on time. Skip any of these and the risk-benefit balance shifts.

Cardiovascular Screening Before the First Injection

Every patient 65 or older should undergo a cardiovascular risk assessment before receiving dose one. The FDA's black box warning on Evenity states that romosozumab "should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" [3]. That warning exists because ARCH showed a statistically significant increase in adjudicated major adverse cardiovascular events (MACE) in the romosozumab arm: 2.5% vs. 1.9% with alendronate over the 12-month active treatment phase [1].

The American Association of Clinical Endocrinology (AACE) 2020 guidelines advise clinicians to weigh the 10-year ASCVD risk score against the 10-year fracture probability from FRAX before prescribing [4]. For patients with a 10-year ASCVD risk above 20%, the guideline explicitly favors denosumab or teriparatide as first-line anabolic options instead.

Practical pre-treatment checklist for the 65+ patient:

• 10-year ASCVD risk calculation (Pooled Cohort Equations)
• 12-lead ECG if no reading within 6 months
• Blood pressure confirmation (two readings on separate days)
• Review of anticoagulant, antiplatelet, and NSAID use
• Documentation of any prior MI, stroke, or TIA

If the ASCVD score and FRAX score both cross their respective high-risk thresholds, shared decision-making with the patient and a cardiologist consult should be documented before proceeding.

Baseline and Ongoing Lab Monitoring

The minimum lab panel at baseline should include serum calcium (corrected for albumin), 25-hydroxyvitamin D, phosphate, magnesium, complete metabolic panel, and eGFR. These values create the reference frame against which every subsequent draw is compared.

Calcium and Vitamin D

Hypocalcemia is the most clinically relevant metabolic risk during romosozumab treatment. The FRAME trial (N=7,180) documented transient decreases in serum calcium within the first month of treatment, with the nadir occurring around week 2 [5]. In older adults with marginal dietary calcium intake, even a modest dip can provoke muscle cramping, QTc prolongation, or confusion.

Replete 25-hydroxyvitamin D to at least 30 ng/mL before the first dose. The Endocrine Society's vitamin D guidelines recommend 1,500 to 2,000 IU daily for adults over 65 at risk of deficiency [6]. Pair this with 1,000 to 1,200 mg of elemental calcium daily from diet plus supplementation.

Recheck serum calcium at month 1 (two weeks after dose 1 is ideal), month 6, and month 12. Any corrected calcium below 8.5 mg/dL warrants dose hold and repletion.

Renal Function

Romosozumab is not renally cleared, but sclerostin inhibition alters mineral metabolism in ways that stress already-compromised kidneys. The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 guidelines note that CKD-mineral bone disorder (CKD-MBD) complicates the interpretation of bone turnover markers in patients with eGFR <45 mL/min/1.73 m² [7]. There is limited trial data for romosozumab in patients with CKD stage 4 or 5, as ARCH excluded patients with eGFR <30.

For patients with eGFR 30 to 59, check eGFR every 3 months during treatment. A decline of more than 15% from baseline should trigger nephrology consultation. For patients with eGFR above 60, a repeat at month 6 is sufficient unless other nephrotoxic medications are co-prescribed.

Bone Density Tracking and Response Assessment

A baseline DXA scan of the lumbar spine, total hip, and femoral neck is required before initiating therapy. The second scan should occur within 1 to 3 months after the final (12th) dose.

In ARCH, romosozumab increased lumbar spine BMD by 13.7% at 12 months compared with 5.0% in the alendronate arm [1]. The FRAME trial reported a 13.3% gain at the lumbar spine and 6.9% at the total hip at month 12 vs. placebo [5]. These are large effect sizes. A geriatric patient who shows less than a 5% gain at the lumbar spine at month 12 may have adherence issues, malabsorption, or an undiagnosed secondary cause of osteoporosis such as multiple myeloma or hyperparathyroidism.

Bone turnover markers (P1NP and CTX) are optional but informative. P1NP typically peaks at month 1 and returns toward baseline by month 9, while CTX declines throughout the 12-month course [8]. Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research & Osteoporosis Center, has noted: "The dual mechanism of romosozumab, stimulating formation while suppressing resorption, makes it unique among osteoporosis therapies, but it also means we see the formation marker window close faster than clinicians expect" [8].

A mid-course P1NP draw at month 6 can reassure both clinician and patient that the drug is still active. If P1NP has already returned to pre-treatment levels by month 6, the remaining doses still suppress resorption, but the formation window has closed earlier than average.

Polypharmacy and Drug Interaction Review

Adults aged 65 and older take a median of five prescription medications according to CDC/NCHS data [9]. Romosozumab itself has no hepatic CYP-mediated interactions, but the medications commonly co-prescribed in this population create indirect risks.

Calcium-channel blockers (amlodipine, diltiazem) can amplify the hypotensive effect of transient hypocalcemia after a romosozumab dose. Loop diuretics (furosemide) increase urinary calcium excretion, raising the floor on supplementation needs. Thiazide diuretics do the opposite, reducing urinary calcium loss. The direction matters for dosing calcium supplements.

Corticosteroids deserve special attention. The American College of Rheumatology 2022 guideline for glucocorticoid-induced osteoporosis recommends osteoporosis treatment for any adult 65 or older taking prednisone at 2.5 mg/day or more for 3 months or longer [10]. If romosozumab is selected for glucocorticoid-induced osteoporosis, concurrent steroid use also suppresses bone formation, potentially blunting the P1NP response and shortening the anabolic window.

A medication reconciliation at baseline and at month 6 should specifically flag:

• Proton pump inhibitors (calcium malabsorption, fracture risk)
• SSRIs (fall risk, bone loss)
• Anticonvulsants (vitamin D catabolism)
• Oral anticoagulants (injection-site hematoma risk)

Cardiovascular Monitoring During the 12-Month Course

Pre-treatment screening is necessary but not sufficient. Ongoing cardiovascular vigilance matters for the full 12 months.

The ARCH trial's MACE signal was not concentrated in one time window. Events accumulated throughout the active treatment period [1]. The 2019 joint statement by the ASBMR and the Endocrine Society acknowledged the cardiovascular signal but stated: "the absolute risk increase was small and must be weighed against the substantial fracture reduction, particularly in patients with the highest skeletal risk" [11].

At each monthly injection visit, document blood pressure and ask about new chest pain, dyspnea on exertion, transient neurological symptoms, or unilateral weakness. Any new symptom warrants holding the next dose pending cardiovascular workup. The monthly visit cadence of romosozumab is actually an advantage here: unlike quarterly denosumab or annual zoledronic acid, it provides 12 face-to-face clinical touchpoints in a year.

For patients with pre-existing atrial fibrillation, ensure INR or anti-Xa levels are current before each injection, as subcutaneous injections carry hematoma risk in anticoagulated patients.

The Transition Plan: What Happens After Dose 12

Romosozumab's bone-forming effect does not persist after treatment ends. Without follow-on antiresorptive therapy, the BMD gains reverse within 12 to 24 months. The FRAME extension data showed that patients transitioned to denosumab maintained and extended their BMD gains through month 24, while those on placebo after romosozumab lost ground [12].

This makes the transition plan a monitoring item, not an afterthought. Document the intended follow-on agent (denosumab 60 mg SC every 6 months or oral alendronate 70 mg weekly are the two most common choices) in the chart at the time of romosozumab initiation.

Dr. Felicia Cosman, professor of medicine at Columbia University and principal investigator on FRAME, has stated: "Failure to consolidate the gains from romosozumab with an antiresorptive agent is, from a fracture-prevention standpoint, equivalent to not having treated at all" [12].

For geriatric patients specifically, the choice between denosumab and a bisphosphonate involves additional considerations:

• Denosumab requires indefinite dosing and carries rebound vertebral fracture risk if discontinued abruptly. In patients with limited life expectancy or poor follow-up reliability, this is a liability.
• Oral bisphosphonates require the patient to sit upright for 30 minutes and swallow with 240 mL of water on an empty stomach. Patients with esophageal strictures, GERD, or cognitive impairment may not tolerate this regimen.
• IV zoledronic acid (5 mg once yearly) bypasses GI concerns but requires monitoring of renal function and carries a small risk of acute-phase reactions (fever, myalgia) that can mimic infection in hospitalized elderly patients.

The first dose of the follow-on agent should be administered within 1 month of the final romosozumab injection. A gap longer than 3 months begins to erode the BMD gains.

Fall-Risk Assessment at Every Visit

Fracture prevention is incomplete without fall prevention. The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 and older at increased fall risk [13]. A Timed Up-and-Go (TUG) test takes 30 seconds and should be performed at baseline and at months 4, 8, and 12.

A TUG time exceeding 12 seconds flags high fall risk. Combine this with a review of footwear, home hazards, visual acuity, orthostatic blood pressure, and sedating medications. The most potent bone-building drug on the market cannot prevent fractures if the patient is falling three times per quarter.

Deprescribing Considerations in the 65+ Population

Geriatric patients on romosozumab should have a deprescribing review focused on medications that accelerate bone loss or increase fall risk. The 2023 AGS Beers Criteria list benzodiazepines, non-benzodiazepine sedative-hypnotics (zolpidem), and first-generation antihistamines as potentially inappropriate in older adults due to fall risk [14].

PPIs prescribed beyond 8 weeks without a documented indication should be tapered when possible. Each year of PPI use after age 65 is associated with a 26% increase in hip fracture risk, per a 2006 JAMA analysis (N=145,000) [15]. Removing a PPI while simultaneously prescribing romosozumab is not contradictory. It is complementary.

Systemic glucocorticoids at any dose should be tapered to the lowest effective level or switched to a steroid-sparing agent when the underlying condition allows.

Month-by-Month Monitoring Timeline

Month 0 (Baseline): ASCVD risk score, FRAX, DXA, serum calcium, 25-OH vitamin D, eGFR, CMP, P1NP, CTX, ECG, medication reconciliation, fall-risk screen, document transition agent.

Month 1: Serum calcium (corrected), 25-OH vitamin D, P1NP. Blood pressure. Assess injection-site reactions.

Months 2 through 5: Blood pressure and symptom check at each injection visit. eGFR at month 3 if CKD stage 3+. TUG at month 4.

Month 6: Serum calcium, 25-OH vitamin D, eGFR, P1NP, medication reconciliation. Reassess ASCVD risk if new cardiovascular symptoms have emerged.

Months 7 through 11: Blood pressure and symptom check at each visit. TUG at month 8. eGFR at month 9 if CKD stage 3+.

Month 12 (Final dose): Serum calcium, eGFR, CTX. Schedule DXA for month 13 or 14. Confirm and schedule first dose of follow-on antiresorptive.

Month 13 to 15: DXA scan. First dose of denosumab or bisphosphonate. Compare BMD to baseline. If lumbar spine gain is <5%, investigate secondary causes.